Literature DB >> 31269540

Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model.

Rob Ter Heine1, Sean P Kane2, Alwin D R Huitema3, Matthew D Krasowski4, Erik M van Maarseveen5.   

Abstract

AIMS: To individualize treatment, phenytoin doses are adjusted based on free concentrations, either measured or calculated from total concentrations. As a mechanistic protein binding model may more accurately reflect the protein binding of phenytoin than the empirical Winter-Tozer equation that is routinely used for calculation of free concentrations, we aimed to develop and validate a mechanistic phenytoin protein binding model.
METHODS: Data were extracted from routine clinical practice. A mechanistic drug protein binding model was developed using nonlinear mixed effects modelling in a development dataset. The predictive performance of the mechanistic model was then compared with the performance of the Winter-Tozer equation in 5 external datasets.
RESULTS: We found that in the clinically relevant concentration range, phenytoin protein binding is not only affected by serum albumin concentrations and presence of severe renal dysfunction, but is also concentration dependent. Furthermore, the developed mechanistic model outperformed the Winter-Tozer equation in 4 out of 5 datasets in predicting free concentrations in various populations.
CONCLUSIONS: Clinicians should be aware that the free fraction changes when phenytoin exposure changes. A mechanistic binding model may facilitate prediction of free phenytoin concentrations from total concentrations, for example for dose individualization in the clinic.
© 2019 The British Pharmacological Society.

Entities:  

Keywords:  fraction unbound; free; in vivo; phenytoin; protein binding

Mesh:

Substances:

Year:  2019        PMID: 31269540      PMCID: PMC6783592          DOI: 10.1111/bcp.14053

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Performance characteristics of four free phenytoin immunoassays.

Authors:  W L Roberts; T M Annesley; B K De; L Moulton; J M Juenke; T P Moyer
Journal:  Ther Drug Monit       Date:  2001-04       Impact factor: 3.681

2.  A major inhibitor of phenytoin binding to serum protein in uremia.

Authors:  H Mabuchi; H Nakahashi
Journal:  Nephron       Date:  1988       Impact factor: 2.847

3.  Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model.

Authors:  Rob Ter Heine; Sean P Kane; Alwin D R Huitema; Matthew D Krasowski; Erik M van Maarseveen
Journal:  Br J Clin Pharmacol       Date:  2019-08-07       Impact factor: 4.335

4.  Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation.

Authors:  Sean P Kane; Adam P Bress; Eljim P Tesoro
Journal:  Ann Pharmacother       Date:  2013-04-19       Impact factor: 3.154

Review 5.  Linking laboratory and medication data: new opportunities for pharmacoepidemiological research.

Authors:  Maarten J ten Berg; Albert Huisman; Patricia M L A van den Bemt; Alfred F A M Schobben; Antoine C G Egberts; Wouter W van Solinge
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

6.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

7.  Population pharmacokinetics of phenytoin in critically ill children.

Authors:  Stefanie Hennig; Ross Norris; Quyen Tu; Karin van Breda; Kate Riney; Kelly Foster; Bruce Lister; Bruce Charles
Journal:  J Clin Pharmacol       Date:  2014-12-04       Impact factor: 3.126

8.  Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds.

Authors:  A Dasgupta; A Abu-Alfa
Journal:  Am J Clin Pathol       Date:  1992-07       Impact factor: 2.493

9.  Evidence-based implementation of free phenytoin therapeutic drug monitoring.

Authors:  M Burt; D C Anderson; J Kloss; F S Apple
Journal:  Clin Chem       Date:  2000-08       Impact factor: 8.327

10.  Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.

Authors:  Philip N Patsalos; David J Berry; Blaise F D Bourgeois; James C Cloyd; Tracy A Glauser; Svein I Johannessen; Ilo E Leppik; Torbjörn Tomson; Emilio Perucca
Journal:  Epilepsia       Date:  2008-07       Impact factor: 5.864

View more
  4 in total

1.  Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model.

Authors:  Rob Ter Heine; Sean P Kane; Alwin D R Huitema; Matthew D Krasowski; Erik M van Maarseveen
Journal:  Br J Clin Pharmacol       Date:  2019-08-07       Impact factor: 4.335

Review 2.  Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States.

Authors:  Marie N Celestin; Florin M Musteata
Journal:  J Pharm Sci       Date:  2021-06-02       Impact factor: 3.784

Review 3.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Authors:  Jason H Karnes; Allan E Rettie; Andrew A Somogyi; Rachel Huddart; Alison E Fohner; Christine M Formea; Ming Ta Michael Lee; Adrian Llerena; Michelle Whirl-Carrillo; Teri E Klein; Elizabeth J Phillips; Scott Mintzer; Andrea Gaedigk; Kelly E Caudle; John T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2020-09-06       Impact factor: 6.875

4.  Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling.

Authors:  Heajin Jun; Yan Rong; Catharina Yih; Jordan Ho; Wendy Cheng; Tony K L Kiang
Journal:  Drugs R D       Date:  2020-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.